The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701).

No abstract

Patients with life-threatening VAs secondary to CAS are at particularly high-risk for recurrence, especially when insufficient medical therapy is administered. Non-dihydropyridine CCBs are capable of suppressing episodes, whereas beta-blocker treatment is predictive of VAs. Ultimately, in spite of medical intervention, some patients exhibited arrhythmogenic events in the long-term, suggesting that ICD implantation may still be indicated for all.

Cardiac anatomy is complex and its understanding is essential for the interventional arrhythmologist. The first difficulty is the terminology used to (PACE 2010; 33:497-507) fluoroscopy, ablation, mapping, anatomy, attitudinal nomenclature IntroductionThe establishment of radiofrequency catheter ablation as the mainstay in the treatment of tachycardia in man has renewed the interest in cardiac morphology. The interventional arrhythmologist has drawn attention not only to the gross anatomic details of the heart, but also to some architectural and histological characteristics of various cardiac regions that are relevant to the understanding of the tachycardia substrates, and the potential complications of catheter ablation. Progress in these areas has not ceased. In this review, therefore, the first of a proposed series, we update and expand previous accounts of cardiac anatomy as seen by the arrhythmologist.

Cardiac implantable electronic devices can accurately detect AF as AHRE. Atrial high rate episodes were associated to a higher incidence of silent IBL on CT scan. Atrial high rate episodes represent a kind of silent AF where management recommendations are lacking despite the fact that a higher embolic risk is present.

IST patients treated with ivabradine showed both HR normalization and quality-of-life improvement maintained in the long-term follow-up. Stopping ivabradine after 1 year unexpectedly showed that HR remained in the normal limits in 80% of the patients.

No abstract

CorVue™ showed a low sensitivity to predict HF events. Therefore, routinely activation of this algorithm could generate misleading information.